Tonix Pharmaceuticals Holding CORP 10-Q quarterly reports

Tonix Pharmaceuticals Holding Corp. reported a substantial increase in net loss for the second quarter of 2026, driven by higher research and development and selling, general, and administrative expenses, while revenue saw significant growth.

Tonix Pharmaceuticals reported a significantly wider net loss in Q1 2026, driven by increased R&D and commercialization costs for its new fibromyalgia drug TONMYA, alongside a going concern warning.

Tonix Pharmaceuticals reports improved net loss and strong cash position, driven by equity raises and FDA approval for its fibromyalgia drug Tonmya, slated for a November 2025 launch.

Tonix Pharmaceuticals reported a significantly reduced net loss and increased cash reserves for Q2 2025, driven by successful financing activities and progress in its drug pipeline, despite ongoing liquidity concerns.

Tonix Pharmaceuticals announces its Q1 2025 financial results, focusing on the regulatory progress of TNX-102 SL for fibromyalgia and ongoing clinical developments.

Tonix Pharmaceuticals submitted a New Drug Application for TNX-102 SL for fibromyalgia and reported a net loss of $14.2 million for the third quarter of 2024.

Tonix Pharmaceuticals reported its Q2 2024 results, including a significant net loss and asset impairments, while also expressing substantial doubt about its ability to continue as a going concern.

Tonix Pharmaceuticals reported a net loss of $14.9 million for Q1 2024, despite generating $2.5 million in product revenue from its newly acquired migraine treatments.